Allogene Therapeutics Inc
Company Profile
Business description
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.
Contact
210 East Grand Avenue
South San FranciscoCA94080
USAT: +1 650 457-2700
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
361
Stocks News & Analysis
stocks
Progress in UK expansion for undervalued ASX share
stocks
The sectors set to soar on government spending
stocks
Chart of the Week: How private companies are reshaping public markets
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,031.70 | 45.20 | -0.50% |
| CAC 40 | 7,950.18 | 14.59 | -0.18% |
| DAX 40 | 23,569.96 | 164.06 | -0.69% |
| Dow JONES (US) | 46,690.07 | 222.23 | -0.47% |
| FTSE 100 | 9,682.57 | 53.21 | -0.55% |
| HKSE | 26,241.83 | 244.07 | -0.92% |
| NASDAQ | 22,723.99 | 330.00 | -1.43% |
| Nikkei 225 | 50,276.37 | 607.31 | -1.19% |
| NZX 50 Index | 13,599.21 | 22.40 | 0.16% |
| S&P 500 | 6,664.69 | 55.63 | -0.83% |
| S&P/ASX 200 | 8,769.70 | 40.80 | -0.46% |
| SSE Composite Index | 3,997.56 | 10.20 | -0.25% |